Selective JAK2/ABL dual inhibition therapy effectively eliminates TKI-insensitive CML stem/progenitor cells.
about
A polymethoxyflavone from Laggera pterodonta induces apoptosis in imatinib-resistant K562R cells via activation of the intrinsic apoptosis pathwayStellettin B induces apoptosis in human chronic myeloid leukemia cells via targeting PI3K and Stat5FZD7 regulates BMSCs-mediated protection of CML cells.CDKIs p18(INK4c) and p57(Kip2) are involved in quiescence of CML leukemic stem cells after treatment with TKI.Identification of Bisindolylmaleimide IX as a potential agent to treat drug-resistant BCR-ABL positive leukemia.Depression of oncogenecity by dephosphorylating and degrading BCR-ABL.Update on emerging treatments for chronic myeloid leukemia.Cellular and Molecular Networks in Chronic Myeloid Leukemia: The Leukemic Stem, Progenitor and Stromal Cell Interplay.Mechanisms of Resistance to ABL Kinase Inhibition in Chronic Myeloid Leukemia and the Development of Next Generation ABL Kinase Inhibitors.Targeting BCR-ABL+ stem/progenitor cells and BCR-ABL-T315I mutant cells by effective inhibition of the BCR-ABL-Tyr177-GRB2 complex.Ruxolitinib/nilotinib cotreatment inhibits leukemia-propagating cells in Philadelphia chromosome-positive ALL.Non ABL-directed inhibitors as alternative treatment strategies for chronic myeloid leukemia.New Mouse Models to Investigate the Efficacy of Drug Combinations in Human Chronic Myeloid Leukemia.
P2860
Q28649477-EE7764F8-E8E8-430A-A730-F16F0D1275F7Q33709955-6E5D7DDD-0B41-41DB-9892-E2BA9821F589Q36905871-E8C14498-0E7E-4E2C-9424-70F97B6D79D8Q36957067-1BB48925-ADF1-430F-8406-39693A20458FQ37688465-0CA5E8FC-A73C-4A30-8496-4B1892D23933Q37709467-1619ECAE-928A-4E95-AC0E-F5C7E5E0696FQ38397515-0E973026-19EA-45C7-9E58-48747DBD852CQ38866390-86E0DA04-B61D-45E8-BD42-DEA0BC6A548BQ39411920-BA90CB09-935B-4491-9570-2F3BBA33B747Q41279430-E5128519-A3B7-482E-8528-59AA3CFA08F6Q41571058-F64EDB52-1659-4852-9FCE-48413DFECF85Q49887884-B9D51C86-0C69-48AA-8D2B-3746386669EEQ55016655-AF0A2673-4B95-4D91-8DC3-A1C0A95513A2
P2860
Selective JAK2/ABL dual inhibition therapy effectively eliminates TKI-insensitive CML stem/progenitor cells.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
2014年论文
@zh
2014年论文
@zh-cn
name
Selective JAK2/ABL dual inhibi ...... ive CML stem/progenitor cells.
@en
type
label
Selective JAK2/ABL dual inhibi ...... ive CML stem/progenitor cells.
@en
prefLabel
Selective JAK2/ABL dual inhibi ...... ive CML stem/progenitor cells.
@en
P2093
P2860
P356
P1433
P1476
Selective JAK2/ABL dual inhibi ...... ive CML stem/progenitor cells.
@en
P2093
Adrian Woolfson
Hanyang Lin
Katharina Rothe
Matthew V Lorenzi
Xiaoyan Jiang
P2860
P304
P356
10.18632/ONCOTARGET.2353
P407
P577
2014-09-01T00:00:00Z